Singapore markets closed

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8600+0.0700 (+2.51%)
At close: 04:00PM EDT
2.8100 -0.05 (-1.75%)
After hours: 05:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.7900
Open2.8100
Bid2.8600 x 100
Ask2.9200 x 100
Day's range2.7700 - 2.8800
52-week range1.7950 - 4.7050
Volume316,518
Avg. volume742,990
Market cap377.414M
Beta (5Y monthly)1.57
PE ratio (TTM)71.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

    CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Management will host a conference call at 5:00 p.m. Eastern Time on May 9th to

  • GlobeNewswire

    Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

    CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with t

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

    CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023. Fourth Quarter 2023 Financial Results Summary: Net revenue of $99.7 million for the fourth quarter of 2023, a decrease of